Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy
|
|
- Loreen Cooper
- 6 years ago
- Views:
Transcription
1 ACTA BIOMED 2007; 78: Mattioli 1885 O R I G I N A L A R T I C L E Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy Emanuele Soncini 1, Alessia Zoncada 2, Vittorio Condemi 1, Anna Degli Antoni 2, Elena Bocchialini 1, Paola Soregotti 1 1 Department of Gynecology, Obstetrics and Neonatology, University of Parma, Parma, Italy; 2 Division of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy Abstract. Background and aim of the work: The purpose of our study was to determine whether highly active antiretroviral therapy (HAART) reduces the onset of cervical intraepithelial neoplasia (CIN) in HIV-positive women. Methods: The study was designed to assess CIN incidence in a cohort of 101 HIV-positive women and to evaluate its relationship with ongoing antiretroviral therapy. The patients were screened through a combined Pap smear and colposcopic examination on a yearly basis. If any abnormalities were reported, the patients underwent targeted biopsy with histological confirmation of the diagnosis. Results: During the follow-up period, 38 patients (37.6%) developed histologically verified CIN, including low-grade CIN in seven patients (6.9%) and high-grade CIN in 31 patients (30.4%). Over the study period, 43 patients (42.6%) were treated with HAART for at least 6 months, the average duration of treatment being 37 months. Analysis of HAART efficacy in preventing CIN onset, determined by the Cox regression model with a time-dependent covariate adjusted for the CD4 level at the first visit, showed that HAART significantly reduced the risk of developing CIN (hazard ratio, 0.3; p = 0.004). Conclusion: HIV-positive patients present a high incidence of CIN and of high-grade CIN in particular. HAART exhibits a protective action against the onset of cervical lesions. ( Key words: Antiretroviral therapy, highly active; cervical intraepithelial neoplasia; cervix neoplasms; vaginal smear; colposcopy; cervix uteri/histopathology; cohort Studies Introduction Invasive cervical carcinoma and its precursors are the most significant gynecologic manifestation of HIV infection and in 1993 cervical cancer was even included among the AIDS-defining conditions (1). In HIV-positive women the annual incidence of squamous intraepithelial lesions (SILs) is estimated to be five times higher than in the general population (8.3/100 vs 1.8/100), with a three-fold risk of developing invasive cervical cancer (2). HIV-positive women also show an increased rate of concurrent HPV infection, especially with serotypes carrying a high risk of SILs (3). Thus, the hypothesis has been advanced that a synergic action of HIV-induced immunosuppression and HPV infection may actually favor the onset of precancerous cervical lesions (4). Highly active retroviral therapy (HAART) regimens have dramatically improved HIV prognosis. However, while systemic benefits are unquestionable, the beneficial actions that it may exhibit locally on the cervix are still unclear. The purpose of this study was to evaluate the effect of HAART on precancerous cervical disease in a population of HIV-positive women.
2 HAART and cervical intraepithelial neoplasia 37 Materials and methods Screening data from Pap smears and colposcopic examinations were collected for all HIV-positive women seen at the Colposcopy and Cervical Pathology Service of the Parma University Hospital, Obstetrics and Gynecology Unit, between January 1993 and December The patients were referred to this Unit from the Parma University Hospital Infectious and Liver Disease Unit within a year of their being admitted to a screening and early-diagnosis program for cervical cancer, either on an outpatient or day hospital basis. As part of the program, at each visit the women undergo a Pap smear and a colposcopic examination. Based on the protocol adopted at the Unit, if the Pap smear test and the colposcopic examination are negative, the women are requested to repeat them after a year; if the Pap smear and/or the colposcopic examination reveal any abnormalities, targeted biopsy is performed and treatment is given based on histological results. Only patients without prior diagnosis of CIN at the first visit are enrolled in the study. For each patient we collected data from the Pap smear and colposcopic examination, as well as from any later biopsy. Pap smear and biopsy results were rated according to the 1991 Bethesda System classification (5). Cytological and histological samples were reviewed by the gynecologic pathologists of the Parma University Hospital Department of Pathology and Laboratory Medicine. Colposcopic examinations were performed by two expert colposcopists; the colposcopic findings were rated according to the International Federation for Cervical Pathology and Colposcopy (IFCPC) classification (6). For each patient we also reviewed clinical records and collected data on the HIV diagnosis date, the level of CD4+ lymphocytes/ µl, and, when possible, the viral load (HIV RNA copies/ml) both determined in the 6 months preceding the Pap smear and the colposcopic examination. HIV RNA plasma levels were measured by the Bayer HIV-1 RNA 3.0 Quantitative Assay (bdna technology) with a sensitivity of ,000 copies/ml. HAART efficacy was evaluated on the basis of the scheduled drug regimen administrated for at least 6 months after the examination: no therapy, single therapy or dual therapy with first-generation antiretrovirals nucleoside analogue reverse transcriptase inhibitors (NRTIs) and HAART based on a combination of three or more drugs. We also collected data from the patients histories on the infection transmission route, drug abuse and cigarette smoking. Statistical analysis was performed using SPSS For statistical analysis, we checked the CD4 and HIV RNA levels versus the stage of cervical disease progression at the last available visit using Student s t-test and the Mann-Whitney U test, respectively. We then assessed the effect of risk factors with the logrank test and the effect of HAART on the SIL incidence rate with the Cox regression model taking HAART as a time-dependent covariate adjusted for the CD4 level at the first visit. Results A total of 120 HIV-positive women were studied in the period between January 1993 and December Of these, 101 did not present a prior diagnosis of SILs at the first visit and had been referred from the Parma University Hospital Infectious and Liver Disease Unit. The baseline epidemiological and clinical features of the 101 patients, including age at HIV diagnosis, age at the first visit, geographic area of origin, infection transmission route, the presence of SIL risk factors, and CD4 lymphocyte count are summarized in Table 1. For these patients we collected data from 340 visits, including 315 with combined Pap smear and colposcopic examination, and 25 with colposcopic examination only. In the data collection process we did not include the visits taken after histological confirmation of the SIL diagnosis, amounting to a total of 236 visits (218 with Pap smear and colposcopic examination, and 18 with colposcopic examination only). Based on the results of the 236 visits considered in the study, 53 biopsies were performed, with positive histological evidence of SILs in 38 cases (71.7%) and negative histological findings in 15 cases (28.3%). During the observation period, 38 patients (37.6%) developed histologically verified SILs, low-grade
3 38 E. Soncini, A. Zoncada, V. Condemi, et al. Table 1. Demographic characteristics and risk factors for cervical intraepithelial neoplasia at enrollment No. (%) Geographic area of origin Italy 82 (81.2%) Sub-Saharan Africa 14 (13.8%) South America 3 (3%) North Africa 1 (1%) Eastern Europe 1 (1%) Risk factors Drug abuse 36 (35.6%) Prostitution 3 (3%) Cigarette smoking 54 (53.5%) Age (years) at HIV diagnosis mean (SD) 29 (7) Transmission route Heterosexual intercourse 61 (60.4%) IV drug abuse 36 (35.6%) Blood transfusion 2 (2%) Unknown 2 (2%) CD4+ cell counts/µl (38.6%) (49.5%) < (11.9%) SD = Standard Deviation (lsil CIN1) in seven patients (6.9%) and high-grade (hsil - CIN2-3) in 31 patients (30.4%). At the time of SIL diagnosis (for the patients who developed the disease) or at the time of the last available visit (for the patients who did not develop the disease), mean CD4 levels appeared significantly lower in SIL patients (303/mm 3 vs 554/mm 3, p<0.001) and in patients with high-grade SILs compared with low-grade SIL patients (278/mm 3 vs 413/mm 3, p = 0.04) (Figure 1). The mean viral load was significantly higher in SIL patients than in non-sil patients: 1.9 vs. 3.2 Log10 (HIV RNA copies)/ml; p = (Figure 2). The Figure 1. Mean CD4 levels at the end of the study and cervical status mean observation period from HIV diagnosis to the last visit was 42 months (range, 6-72 months). During the study, 31 patients (30.7%) did not recieve antiretroviral therapy, 27 patients (26.7%) were given only one or two NRTIs for at least 6 months, 13 patients (12.9%) were given both first-generation antiretrovirals and then HAART, and 30 patients (29.7%) were given only HAART for a period of at least 6 months. Overall, 43 patients (42.6%) received HAART for at least 6 months, the average duration of treatment being 37 months (range, 7-60 months). The HAART Table 2. Cervical biopsy results in the observation period Biopsy diagnosis No (%) LSIL (CIN1) 7 (6,9%) HSIL (CIN2-3) 31 (30,7%) Total SIL 38 (37,6%) LSIL = Low-Grade Squamous Intraepithelial Lesions HSIL = High-Grade Squamous Intraepithelial Lesions CIN = Cervical Intraepithelial Neoplasia Figure 2. Mean viral load at the end of the study and cervical status
4 HAART and cervical intraepithelial neoplasia 39 Table 3. Univariate and multivariate analysis of risk factors for cervical intraepithelial neoplasia Univariate analysis HR CI 95% p Drug abuse 1.61 ( ) 0.14 Cigarette smoking 0.91 ( ) 0.77 CD4 count 2.26 ( ) HAART 0.3 ( ) Multivariate analysis Adjusted HR CI 95% p CD4 count 2.38 ( ) HAART 0.3 ( ) HR = Hazard Ratio; CI = Confidence Interval regimen included two NRTIs + one protease inhibitor (PI) in 20 patients (46.5%), two NRTIs + one nonnucleoside reverse transcriptase inhibitor (NNRTI) in 18 patients (41.9%), and three NRTIs in 5 patients (11.6%). Univariate analysis of risk factors through survival curves and the log-rank test showed that low CD4 levels were associated with an increased SIL risk (hazard ratio = 2.26), but were not correlated with cigarette smoking and drug abuse. Multivariate analysis of HAART efficacy in preventing SIL onset was performed using the Cox regression model with a time-dependent covariate adjusted for the CD4 level at the first visit. It showed that HAART significantly reduced the risk of developing SILs (hazard ratio, 0.3; p = 0.004) (Table 3). Conclusions HAART has dramatically changed the natural history of HIV, strongly increasing CD4+ lymphocyte levels, reducing the incidence of AIDS-related diseases, and prolonging survival. Immunosuppression, characterized by a progressive decline of CD4 lymphocyte levels, is correlated with the onset of CIN and of high-grade CIN in particular (2). Our study results confirm this close correlation. Recent studies have indicated that HAART may show a beneficial effect on cervical diseases, but evidence is still too scant. In a study on 96 patients treated with antiretroviral drugs, Heard observed a positive correlation between regression of cervical lesions and improvement of the immunitary system (7). In a subsequent study, Heard found that CD4 cell counts <200/mm 3 and a positive margin were predictors of recurrence, whereas HAART had a strong protective effect (8). Minkoff found a reduced progression and an increased regression of lesions (9). Finally, Robinson demonstrated that patients treated with HAART have a lower risk of CIN relapse, persistence and progression (10). In our study, we observed the onset of CIN in a large number of patients (37.3%) with a large proportion of high-grade cases (30.4%). The higher the CIN grade, the worse the viral immunological state of the patient. As we took only HAART as a time-dependent covariate in our comparison, we could not investigate the efficacy of antiretroviral therapy with NRTIs alone. The fact that HAART has been proved effective in reducing the risk in the treated group versus the control group of patients not treated with HAART, regardless of whether they were given or not NRTIs, indirectly supports evidence of the inefficacy or lower efficacy of non-haart regimens in preventing CIN onset. This finding is in agreement with a pre-haart study by Ellerbrock (2), who did not find any differences in the incidence of cervical disease between patients given antiretroviral-therapy compared to those who were not treated. A limiting factor of our study is the lack of information on the HPV state of the patients. Very few studies have considered the association between HIV, HPV correlated cervical lesions and HAART therapy. To date, the available data suggest that the widespread use of HAART has not led to reduced prevalence of genital HPV infection in HIV-positive women (7, 11). A recent report has shown that antiretroviral therapy does not prevent the development of HPV-associated lesions and does not eliminate HPV infection (12), however in the same study regression of low-grade lesions was more prevalent among patients receiving highly active antiretroviral therapy than among those receiving other regimens. The conflicting findings of literature suggest that further studies on larger case series are needed to evaluate whether HAART-induced reduction of the risk of developing SILs will be sufficient to change the aggressive approach to cervical disease screening currently recommended by several authors and authoritative clinical guidelines (2, 7, 13).
5 40 E. Soncini, A. Zoncada, V. Condemi, et al. References revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283: Jan N, Moscicki AB. Human papillomavirus infections in women with HIV disease: prevalence, risk, and management. AIDS Read 2000; 10: Heard I, Tassie J, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G: Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet Gynecol 2000; 96: The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, April 29-30, Acta Cytol 1993; 37: Coppleson M, Pixley E. International colpolscopic terminology. In Coppleson M. (ed): Gynaecological Oncology. Edinburg: Churchill Livingstone, Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002; 16: Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine MD. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr 2005; 39: Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15: Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184: Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: Del Mistro A, Bertorelle R, Franzetti M, et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 2004; 38: Sexually transmitted diseases treatment guidelines Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51(RR-6): Accepted: 22 th October 2006 Correspondence: Emanuele Soncini, MD, PhD. Department of Gynecology, Obstetrics and Neonatology, University of Parma, Viale A. Gramsci, Parma, Italy Tel Fax soncio@tin.it,
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationORIGINAL ARTICLES. Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town. Methods
Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town Priya Batra, Louise Kuhn, Lynette Denny Objective. An audit of outcomes of cervical cancer screening
More informationHuman Papillomavirus Prevalence, Viral Load and Cervical Intraepithelial Neoplasia in HIV-Infected Women
BJID 2002; 6 (June) 129 Human Papillomavirus Prevalence, Viral Load and Cervical Intraepithelial Neoplasia in HIV-Infected Women José E. Levi, Maria C.S. Fink, Cynthia L.M. Canto, Nadily Carretiero, Regina
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationA study of prevalence of Pap smear abnormalities in HIV seropositive women
Original Research Article A study of prevalence of Pap smear abnormalities in HIV seropositive women Yamini Shoba Vani 1*, Muddasani Priyadharshini 2 1 Assistant Professor, 2 Post Graduate Department of
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationGenital Dysplasia in Women Infected with Human Immunodeficiency Virus
Genital Dysplasia in Women Infected with Human Immunodeficiency Virus Gregory Taylor, MD, Tracy Wolff, MD, Niharika Khanna, MD, Priscilla Furth, MD, and Patricia Langenberg, PhD* Background: Women infected
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationEffect of HIV Infection on Atypical Squamous Cells of Undetermined Significance
MAJOR ARTICLE HIV/AIDS Effect of HIV Infection on Atypical Squamous Cells of Undetermined Significance Ann Duerr, 1 Pangaja Paramsothy, 2 Denise J. Jamieson, 3 Charles M. Heilig, 3 Robert S. Klein, 4 Susan
More informationHPV the silent killer, Prevention and diagnosis
HPV the silent killer, Prevention and diagnosis HPV Human Papilloma Virus is a name given for a silent virus transmitted sexually most of the time, a virus that spreads in the name of love, passion, and
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationCytyc Corporation - Case Presentation Archive - June 2003
ThinPrep General Cytology History: Asymptomatic 35 Year Old Male Specimen type: Anal Cytology - This specimen was collected using a Dacron swab under proctoscopic visualization. This case was provided
More informationThe Prevalence of Human Papillomavirus and Cervical Cytology Abnormalities in Women Infected with Human Immunodeficiency Virus in Southern Israel
Original Articles IMAJ VOL 13 JANUARY 2011 The Prevalence of Human Papillomavirus and Cervical Cytology Abnormalities in Women Infected with Human Immunodeficiency Virus in Southern Israel Lilach Leibenson
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationScreening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck
Screening for Cervical Cancer Grand Rounds 1/16/13 Meggan Linck Cervical Cancer Worldwide 2 nd most common and 5 th deadliest U.S. 8 th most common 80% occur in developing world Median age at diagnosis
More information9/18/2008. Cervical Cancer Prevention for Adolescent Populations Garcia. Faculty disclosure. Objectives. HPV Positivity by Age (UK)
Faculty disclosure Cervical Cancer Prevention for Francisco, MD, MPH Associate Professor Obstetrics & Gynecology Mexican American Studies Public Health Francisco, MD, MPH has no financial affiliations
More informationAnal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy
MAJOR ARTICLE Anal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy T. J. Wilkin, 1 S. Palmer, 2 K. F. Brudney, 3 M. A. Chiasson, 3,5 and
More informationCase Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure
Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This
More informationAcceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index
DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationA RETROSPECTIVE REVIEW OF CERVICAL SMEARS IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED POSTNATAL WOMEN AT JOHANNESBURG HOSPITAL.
A RETROSPECTIVE REVIEW OF CERVICAL SMEARS IN HUMAN IMMUNODEFICIENCY VIRUS INFECTED POSTNATAL WOMEN AT JOHANNESBURG HOSPITAL Amy Juliet Wise A research report submitted to the Faculty of Health Sciences,
More informationDone by khozama jehad. Neoplasia of the cervix
Done by khozama jehad Neoplasia of the cervix An overview of cervical neoplasia very import. Most tumors of the cervix are of epithelial origin and are caused by oncogenic strains of human papillomavirus
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationAlthough rare, a significant increase in incidence
Original Research Concurrent Anal Human Papillomavirus and Abnormal Anal Cytology in Women With Known Cervical Dysplasia Jacqueline Lammé, MD, Tina Pattaratornkosohn, MD, Joselyn Mercado-Abadie, MD, Addie
More informationJean Anderson, MD Catherine Sewell, MD, MPH
Jean Anderson, MD Catherine Sewell, MD, MPH To review diagnosis and management of HPV disease in the setting of HIV infection and address controversies HIV-infected women have: higher prevalence and incidence
More informationThe routine use of ZedScan within one colposcopy service in England. MC Macdonald, R Lyon, JE Palmer, JA Tidy
The routine use of ZedScan within one colposcopy service in England MC Macdonald, R Lyon, JE Palmer, JA Tidy Introduction Colposcopic impression alone has been shown to be subjective with variable rates
More informationStudy Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14 SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationMolecular markers for diagnosis and prognosis in cervical neoplasia Eijsink, Jasper Johannes Hendrikus
University of Groningen Molecular markers for diagnosis and prognosis in cervical neoplasia Eijsink, Jasper Johannes Hendrikus IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationPrevalence and risk factors for cervical intraepithelial neoplasia among HIV-infected women
BRAZ J INFECT DIS. 2012;16(2):164-169 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original Article Prevalence and risk factors for cervical intraepithelial neoplasia among
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationTISSUE TUMOR MARKER EXPRESSION IN
TISSUE TUMOR MARKER EXPRESSION IN NORMAL CERVICAL TISSUE AND IN CERVICAL INTRAEPITHELIAL NEOPLASIA, FOR WOMEN WHO ARE AT HIGH RISK OF HPV (HUMAN PAPILLOMA VIRUS INFECTION). Raghad Samir MD PhD Verksamhet
More informationHIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco
Anal cytology and anal cancer in HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco April 10, 2010 Disclosures Merck and Co: Research grant support, advisory boards
More informationOver-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationHCT Medical Policy. High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014.
HCT Medical Policy High-Resolution Anoscopy for Evaluation of Anal Lesions Policy # HCT109 Current Effective Date: 10/30/2014 Medical Policies are developed by HealthyCT to assist in administering plan
More informationDepartment of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal
Kathmandu University Medical Journal (2007), Vol. 5, No. 4, Issue 20, 461-467 Original Article Correlation of PAP smear findings with clinical findings and cervical biopsy Pradhan B 1, Pradhan SB 2, Mital
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationHPV, Cervical Dysplasia and Cancer
FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and
More informationCervical Screening Recommendation for non HIV-infected Immunosuppressed Women
Cervical Screening Recommendation for non HIV-infected Immunosuppressed Women Chair: Anna-Barbara Moscicki Team (in alphabetic order): Lisa Flowers, Michael Gold, Megan Huchko, Margaret Long, Kathy MacLaughlin,
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationProfile Of Cervical Smears Cytology In Western Region Of Saudi Arabia
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 1 Number 2 Profile Of Cervical Smears Cytology In Western Region Of Saudi Arabia I Mansoor Citation I Mansoor. Profile Of Cervical Smears
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY EFFECTIVE DATE: 12/20/12 REVISED DATE: 11/21/13, 10/16/14, 09/17/15, 9/15/16 ARCHIVED DATE: 09/21/17
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationCERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.
CERVIX MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb. CERVIX Most cervical lesions are: Most are Cervicitis. cancers ( common in women worldwide). CERVICITIS Extremely
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationHuman Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita
Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is
More informationClinical Care of Gynecological Problems in HIV. Howard P Manyonga SA HIV Clinicians Society Conference 26 September 2014
Clinical Care of Gynecological Problems in HIV Howard P Manyonga SA HIV Clinicians Society Conference 26 September 2014 Outline List of problems is long! Abnormal uterine bleeding (AUB) Menopause HIV and
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationComparison of HPV Infection and Cervical Disease Between HIV-infected and HIV-uninfected Adolescent Females in Cape Town, South Africa
Comparison of HPV Infection and Cervical Disease Between HIV-infected and HIV-uninfected Adolescent Females in Cape Town, South Africa Purpose of Study The purpose of this study is to investigate the difference
More informationManagament of Abnormal Cervical Cytology and Histology
Managament of Abnormal Cervical Cytology and Histology Ali Ayhan, M.D Başkent University Faculty of Medicine Department of Gynecology and Obstetrics Division of Gynecologic Oncology Abnormal Cytologic
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationThe implications of HPV immunisation on cervical screening
The implications of HPV immunisation on cervical screening Dr Maggie Cruickshank Senior Lecturer in Gynaecology Scottish Cervical Cancer Prevention Programme (SCCPP) funded by CSO Cervical screening Detects
More informationAGC Subclasses and Risk of Invasive Cancers
AGC Subclasses and Risk of Invasive Cancers Xuezhi (Daniel) Jiang, MD, PhD Associate Professor of Obstetrics & Gynecology The Reading Hospital of Tower Health Thomas Jefferson University Reading, PA Disclosures
More informationA Case Control Study of HPV and Abnormal Cervical Cytology Among HIV Infected and Non Infected Females
A Case Control Study of HPV and Abnormal Cervical Cytology Among HIV Infected and Non Infected Females Kavita Karmacharya 1, Rajiv B Batra 2 and Subramaniam Kandasamy 3 1: Department of Pathology, Nepalese
More informationHIV in Obstetrics and Gynecology
FAST FACTS HIV in Obstetrics and Gynecology Indispensable Guides to Clinical by J Richard Smith, Naomi Low-Beer and Bruce A Barron Practice HIV infection 7 Managing infected women 13 Preconceptual care
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationAnal Cytology as a Screening Tool for Early Detection of Anal Dysplasia in HIV-infected Women
Anal Cytology as a Screening Tool for Early Detection of Anal Dysplasia in HIV-infected Women ANDREA GINGELMAIER, TOBIAS WEISSENBACHER, BERND KOST, RALPH KAESTNER, MILENA SOVRIC, IOANNIS MYLONAS, KLAUS
More informationHUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS
HUMAN PAPILLOMAVIRUS INFECTION IN WOMEN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS XIAO-WEI SUN, M.D., LOUISE KUHN, PH.D., TEDD V. ELLERBROCK, M.D., MARY ANN CHIASSON, DR.P.H., TIMOTHY J. BUSH, B.A.,
More informationI have no financial interests to disclose.
Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics I have no financial interests
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationClinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages years
Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages 21-39 years Michelle I. Silver, PhD, ScM Cancer Prevention Fellow National Cancer Institute Division of Cancer
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 8 No ISSN 75 876 Findings and outcome of teenage women referred for colposcopy at Christchurch Women s Hospital, New Zealand Peter Sykes, Dianne Harker, David Peddie
More informationCervical Cancer Screening Update. Melissa Hartman, DO Women s Health
Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse
More informationA longitudinal study of HPV detection and cervical pathology in HIV infected women
Sex Transm Inf 2000;76:257 261 257 Original article Regional Clinical Virology Laboratory, Lothian University Hospitals NHS Trust H A Cubie A L Seagar Department of Obstetrics and Gynaecology, West Lothian
More informationEpidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract
Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract Kevin Ault, Emory University Journal Title: Infectious Diseases in Obstetrics and Gynecology Volume: Volume
More informationHIV infection is an increasingly widespread disease, with a growing
ORIGINAL ARTICLE Prevalence of colpocytological abnormalities in pregnant HIV-positive women and risk factors Francesco Maria Crupano MD, Angela Miccoli MD, Maria Calabretti MD, Alessandra Caterina De
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More informationManagement of Abnormal Cervical Cytology and Histology
Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPREVENTION OF CERVICAL CANCER
PREVENTION OF CERVICAL CANCER Author: Dr R. Fuentes MBchb, Havana Spec. OB,GY-Havana- 2011 CONTENT TABLE Abbreviations 2 Introduction 4 The natural history of Cervical cancer 4 Risk Factors 4 Incidence
More informationHPV/Cervical Cancer Resource Guide for patients and providers
DHS: PUBLIC HEALTH DIVISION IMMUNIZATION PROGRAM HPV/Cervical Cancer Resource Guide for patients and providers Independent. Healthy. Safe. Oregon HPV Provider Resource Kit: Table of Contents Provider Information
More informationTHE TREATMENT AND EVOLUTION OF CERVICAL CANCER
Analele tiin ifice ale Universit ii Alexandru Ioan Cuza, Sec iunea Genetic i Biologie Molecular, TOM XII, 20 THE TREATMENT AND EVOLUTION OF CERVICAL CANCER EDUARD CRAUCIUC, MARIANA BRATU 3, DORIN NEACSU,
More informationTHE PERFORMANCE OF CEPHEID XPERT HPV
THE PERFORMANCE OF CEPHEID XPERT HPV Zizipho Z.A Mbulawa, Timothy Wilkin, Bridgette J. Goeieman, Eefje Jong, Pamela Michelow, Avril Swarts, Jennifer S. Smith, Patricia Kegorilwe, Cynthia S. Firnhaber,
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationWhat is a Pap smear?
Pap smear What is a Pap smear? A Pap smear is a test that checks for changes in the cells of your cervix. The cervix is the lower part of the uterus that opens into the vagina. Developed over forty years
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationAssociate Professor of Gyn. & Obs., Department of Gynecology and Obstetrics, Tehran University of Medical Sciences, Iran.
Assessment of Visual Inspection with Acetic Acid (VIA) as a Screening Test for Cervical Neoplasia in Comparison with Cytologic Screening in Imam Khomeini Hospital F. Ghaemmaghami, MD Associate Professor
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationAn evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme Sherlaw-Johnson C, Philips Z
An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme Sherlaw-Johnson C, Philips Z Record Status This is a critical abstract of an economic
More informationPatients referred to a colposcopy clinic will often have
The Accuracy of the Papanicolaou Smear in the Screening and Diagnostic Settings Marylou Cárdenas-Turanzas, MD, DrPH, 1 Michele Follen, MD, PhD, 2 Graciela M. Nogueras-Gonzalez, MPH, 1 J.L. Benedet, MD,
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More information